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Human herpesvirus 8 (HHV-8; Kaposi’s sarcoma-associated herpesvirus) is an oncogenic
gammaherpesvirus that primarily infects cells of the immune and vascular systems.
HHV-8 interacts with and targets professional antigen presenting cells and inﬂuences
their function. Infection alters the maturation, antigen presentation, and immune acti-
vation capabilities of certain dendritic cells (DC) despite non-robust lytic replication in
these cells. DC sustains a low level of antiviral functionality during HHV-8 infection
in vitro. This may explain the ability of healthy individuals to effectively control this virus
without disease. Following an immune compromising event, such as organ transplantation
or human immunodeﬁciency virus type 1 infection, a reduced cellular antiviral response
against HHV-8 compounded with skewed DC cytokine production and antigen presentation
likely contributes to the development of HHV-8 associated diseases, i.e., Kaposi’s sarcoma
and certain B cell lymphomas. In this reviewwe focus on the role of DC in the establishment
of HHV-8 primary and latent infection, the functional state of DC during HHV-8 infection,
and the current understanding of the factors inﬂuencing virus-DC interactions in the context
of HHV-8-associated disease.
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BACKGROUND
Human herpesvirus 8 (HHV-8) is one of eight herpesviruses
known to infect and establish chronic latency in humans.
Also known as Kaposi’s sarcoma-associated herpesvirus (KSHV),
HHV-8 was ﬁrst identiﬁed as a gammaherpesvirus in 1994 in
AIDS patients with Kaposi’s sarcoma (KS; Chang et al., 1994).
HHV-8 has since been recognized as the causal agent of all four
distinct forms of KS: classic KS in elderly European and Mediter-
ranean men, endemic KS in human immunodeﬁciency virus type
1 (HIV-1) negativeAfricanpopulations, iatrogenicKS in immuno-
suppressed patients post-transplantation, and AIDS-KS in HIV-1
infected populations. It is also acknowledged as a common factor
in the development of two B cell lymphomas, i.e., primary effu-
sion lymphoma (PEL) and a subset of Castleman’s disease cases
known as multicentric Castleman’s disease (MCD; Chang et al.,
1994; Cesarman et al., 1995; Soulier et al., 1995; Nador et al., 1996;
Cesarman and Knowles, 1999).
This double-stranded DNA virus targets several cell types for
infection in vivo and in vitro where it either replicates or estab-
lishes latency. Of particular interest is thatHHV-8 targets so-called
professional antigen presenting cells (APC) including monocyte-
derived dendritic cells (MDDC; Rappocciolo et al., 2006a), B
cells (Ambroziak et al., 1995; Rappocciolo et al., 2008; Myoung
and Ganem, 2011) and monocytes (Blasig et al., 1997), as well
as endothelial cells (Boshoff et al., 1995). Indeed, while HHV-8
infected and uninfected endothelial and spindle cells form neo-
plastic KS lesions (Boshoff et al., 1995), infected and uninfected B
cells and monocytes are found proximal to KS lesions (Ambroziak
et al., 1995; Blasig et al., 1997). The role of dendritic cells (DC)
in antigen presentation and immune activation suggests these
functions, or lack thereof, could be involved in the develop-
ment of HHV-8 diseases associated with a compromised immune
system.
Myeloid dendritic cells (mDC), including Langerhan cells (LC),
skin dermal dendritic cells (DDC), submucosal dermal dendritic
cells (SMDC), and MDDC, have essential roles in both the innate
and adaptive immune response to primary and subsequent infec-
tions as well as reactivation of chronic viral infections. They
act during the innate immune response as specialized cells that
survey and detect antigens of foreign microorganisms through-
out the body thereby inducing their ability to communicate
with helper and effector lymphocytes to bridge the innate and
adaptive response (Clark et al., 2000; Geissmann et al., 2010).
In addition, plasmacytoid dendritic cells (pDC) of lymphoid
origin recognize single-stranded RNA and unmethylated CpG
motifs associated with viral infection to help induce an antivi-
ral response within the host (West et al., 2011). Infection of
monocytes and DC by both gammaherpesviruses, HHV-8 and
Epstein–Barr virus (EBV), has been shown to diminish the
subsequent T cell response (Li et al., 2002; Rappocciolo et al.,
2006a; Hensler et al., 2009). However, the manner in which DC
infection alters the cellular response associated with HHV-8 infec-
tion and its impact on HHV-8 associated disease is minimally
understood.
Despite multiple attempts to generate reliable animal models
of HHV-8-associated diseases, the overall lack of suitable in vivo
models has limited HHV-8 pathogenesis research. A humanized-
BLT mouse model has recently been successfully used to establish
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lytic and latent infection in human B cells and macrophages
(Wang et al., 2014), and augurs well for future research on
HHV-8. Here we focus on the role of DC in the establishment
of HHV-8 primary and latent infection predominantly using in
vitro models, including the functional state of DC during HHV-8
infection and the current understanding of the factors inﬂuenc-
ing virus – DC interactions in the context of HHV-8-associated
disease.
CELLULAR RECEPTORS FOR HHV-8 INFECTION
ATTACHMENT RECEPTORS
The establishment of HHV-8 infection requires two separate
events at the surface of susceptible cells – namely binding to an
attachment receptor followed by binding to one or more entry
receptors. Prior to the initiation of virus entry, attachment occurs
by the direct interactions of viral glycoproteins B (gB) and K8.1
with the attachment receptor heparan sulfate (HS) on the cell
surface (Akula et al., 2001a,b; Birkmann et al., 2001; Wang et al.,
2001a). This has been supported by evidence that soluble heparin,
a molecule similar in structure to HS, blocks HHV-8 attachment
to ﬁbroblasts in a dose-dependent manner (Akula et al., 2001b).
However, soluble heparin is not sufﬁcient to completely block
HHV-8 infection of ﬁbroblasts or endothelial cells (Akula et al.,
2001b; Birkmann et al., 2001), suggesting that virus entry is a
multi-step process and there may be other attachment factors
involved. Yet, the ubiquitous nature of HS expression on host
cells may explain the broad range of cellular targets of this virus.
ENTRY RECEPTORS
Several receptors in the extracellular matrix have been impli-
cated in HHV-8 entry of different human cell types. Dendritic
cell-speciﬁc ICAM-3-grabbing non-integrin (DC-SIGN) has been
revealed as a receptor for HHV-8 infection of MDDC, monocytes,
and monocyte-derived macrophages (Rappocciolo et al., 2006a;
Kerur et al., 2010), as well as B cells (Rappocciolo et al., 2008).
More recently we have shown that gB of HHV-8 binds to DC-
SIGN (Hensler et al., 2014). In addition, our group has shown
that HHV-8 infection of MDDC is associated with a decrease in
DC-SIGN expression (Rappocciolo et al., 2006a). Integrin α3β1
has been demonstrated as a cellular receptor for HHV-8 infection
on vascular endothelial cells and foreskin ﬁbroblasts (Akula et al.,
2002). Most recently, the ephrin receptor tyrosine kinase A2 has
been found to serve as a receptor for HHV-8 infection mediated by
interactions with the viral glycoprotein L and H dimer, speciﬁcally
on HS-negative cells (Hahn et al., 2012), which had previously
been identiﬁed as a viral surface complex essential for entry into
susceptible host cells (Campadelli-Fiume et al., 2007). Interest-
ingly, this receptor has been shown to be expressed on LC (Munthe
et al., 2004), suggesting that these cells could be susceptible to
HHV-8 infection.
These reports support that HHV-8 is capable of recogniz-
ing multiple receptors on human host cells, and emphasize
that our understanding of HHV-8 attachment, entry, and pos-
sibly spread throughout the host is still limited. Minimal data
exist demonstrating the role of gL and gH in HHV-8 infection,
speciﬁcally on HS-positive cells that likely use HS as an initial
receptor for attachment. The viral gB has been demonstrated
to bind to both DC-SIGN and the integrin α3β1 (Akula et al.,
2002; Sharma-Walia et al., 2004). It is unclear whether either
receptor alone is sufﬁcient for both viral attachment and entry.
HHV-8 (like other human herpesviruses) likely utilizes receptor
ﬂexibility to expand the range of cell types it infects and adapt
to different immunological environments that it encounters in
the host.
HHV-8 TRANSMISSION
MUCOSAL TRANSMISSION
The oral cavity is the most common portal of entry and route
of transmission for HHV-8 (Pica and Volpi, 2007) leading to
inevitable virus exposure to mucosal surfaces of the oropharynx.
In fact, HHV-8 DNA can be detected by PCR from intact viri-
ons in the majority of saliva samples from seropositive individuals
(Koelle et al., 1997; Vieira et al., 1997). Given the strategic posi-
tions of LC and SMDC at the mucosal sites, these cells could be
the ﬁrst targets of HHV-8 infection. The primary role of such
mDC is the detection, uptake, and processing of foreign microbes
for antigen presentation to T cells in secondary lymphoid organs,
an efﬁcient method of activating the adaptive immune response
and establishing immunologicmemory against invaders. Based on
this function of mDC, they are constantly exposed to and inter-
acting with pathogens and are thereby likely targets of HHV-8
infection. LC are the primary subset of DC found in the epidermal
layer of the skin and within the epithelia lining mucosal surfaces
(Iwasaki, 2007), both of which are functional physical barriers
that serve as the primary defense mechanism against pathogens.
Although LC do not express the HHV-8 entry receptor DC-SIGN
(Soilleux and Coleman, 2001; Soilleux et al., 2002), they do express
the HHV-8 attachment receptor HS on their surface (Yan et al.,
2004). LC also express langerin, a type II transmembrane C-type
lectin which could potentially be also acting as a receptor for
HHV-8 (Valladeau et al., 2000). Interestingly, langerin has been
shown to bind HIV-1 and subsequently transport it to the Bir-
beck granules for degradation, thus forming a protective barrier
to HIV-1 dissemination (de Witte et al., 2007). Such studies of
LC in HHV-8 infection are hampered by difﬁculties in obtain-
ing human LC in sufﬁcient quantities and a natural homeostatic
state. Alternatively, susceptibility to HHV-8 infection could be
assessed using an established in vitro model of deriving LC from
CD34+ hematopoietic cells (Ratzinger et al., 2004). Interestingly,
infection of LC plays a role in the pathogenesis of EBV (Walling
et al., 2007). Whether LC are targets for HHV-8 infection, and
langerin acts as a receptor or protective factor, may open a new
avenue toward understanding HHV-8 establishment of latency
and reactivation.
In addition to LC, SMDC are found in lamina propria below
the epithelial surface of the oral cavity (Cutler and Jotwani,
2006). In vitro and in vivo HHV-8 infection of SMDC has yet
to be shown. Nonetheless, unlike LC, SMDC express DC-SIGN
(Cutler and Jotwani, 2006) suggesting that they are permissive to
HHV-8 infection (Rappocciolo et al., 2006a). In conclusion, due to
their physical location and central function in T cell activation, it
would be physiologically relevant for HHV-8 to target mucosal
residing DC for replication and transport into the lymphatic
system.
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Human herpesvirus 8 transmission through the genital tract
is considered less likely due to the lower levels of detectable
virus found in semen and vaginal secretions compared to saliva
(Edelman, 2005). However, it is still a major route of transmission
and of great concern in high-risk endemic communities (Pica and
Volpi, 2007). Interestingly, HHV-8 has been detected in tissue of
normal non-cancerous prostates from men who have succumbed
to AIDS (Montgomery et al., 2006). HHV-8 can also be detected
in cervicovaginal secretions of HIV-1/HHV-8 co-infected women
(Lisco et al., 2006), and although it is rare, vertical transmis-
sion of HHV-8 has been recorded (Brayﬁeld et al., 2003). LC and
SMDC are both found within the epithelial lining of the ecto-
cervix and the vagina (Iwasaki, 2007). The function of immune
cells in the female reproductive tract is known to be heavily
controlled byhormoneproduction, and their phenotype and func-
tion is not fully understood (Iwasaki, 2007). Therefore, based
on possible differences in receptor expression, the susceptibility
of genital tract DC to HHV-8 infection may vary compared to
their counterparts in oral mucosa, which could at least in part
explain the differential transmission seen between oral and sexual
routes.
BLOOD-BORNE TRANSMISSION
Human herpesvirus 8 can be transmitted through exposure
to infectious blood products. Cases of HHV-8 seroconversion
associated with blood transfusion, organ transplantation, and
intravenous drug use have been reported, however, the latter may
be indicative of other high-risk behaviors associated with drug use
(Pica andVolpi, 2007). Blood-borne transmission directly exposes
immune cells circulating in the vascular system, such as mDC, to
the virus much quicker than natural exposure through the oral or
genital route. mDC are sparsely distributed throughout the body
(Banchereau and Steinman, 1998), which has made them difﬁcult
to study. The development of an in vitro model of deriving MDDC
from peripheral blood monocytes with GM-CSF and interleukin
4 (IL-4; Sallusto and Lanzavecchia, 1994) eased the study of this
DC subpopulation, as they closely resemble the function of in vivo
mDC (Qu et al., 2009; Cheong et al., 2010). The in vitro derived
MDDC express DC-SIGN on their surface through which HHV-8
enters and establishes low levels of lytic replication, but display lit-
tle viral DNA turnover (Rappocciolo et al., 2006a). Differences in
primary sites of HHV-8 infection likely inﬂuence the host response
to infection. Due to a non-robust replication cycle within MDDC
and little evidence that LC and SMDC support HHV-8 replication,
it is likely the virus also spreads further into the host through cells
other than DC.
HHV-8 INFILTRATION OF THE LYMPHATIC SYSTEM
TRAFFICKING TO LYMPHOID ORGANS
How HHV-8 travels to and infects cells within secondary lym-
phoid tissue is not fully understood. The mucosal immune system,
both oral and urogenital, is highly sensitized to the detection of
and protection from foreign microbes. However, when an organ-
ism breaches this primary line of defense, resident immune cells
detect the intrusion and produce pro-inﬂammatory cytokines.
Such soluble molecules increase the migration of maturing LC
and SMDC into the mucosal lamina propria (Jotwani and Cutler,
2003) where they engulf foreign antigen, upon which lymphatic
homing receptors are up-regulated, such as CCR7, to attract
them to CCL19 and CCL21 expressing high endothelial venules
(HEVs). This triggers APC migration into lymphatic vessels and
trafﬁcking to draining lymph nodes where the foreign antigen is
presented to effector T and B cells (Holmgren and Czerkinsky,
2005).
Humanherpesvirus 8 likely travels to draining lymphoidorgans
within DC and monocytes from the primary site of infection,
where it can then interact with resident B and T cells. Lytic HHV-8
infection of oral epithelium occurs in vitro (Duus et al., 2004),
and has been detected in vivo in monocytes within the cuta-
neous, highly vascularized lesions of KS patients (Blasig et al.,
1997). Macrophages found in tissues and monocytes in periph-
eral blood travel to draining lymph nodes upon stimulation by
foreign microbial antigens, and function in antigen presenta-
tion. Macrophages treated with IL-13 express DC-SIGN (Chehimi
et al., 2003), resulting in their susceptibility to abortive infection
with HHV-8 (Rappocciolo et al., 2006a). Moreover, tissue resident
macrophages express DC-SIGN (Soilleux et al., 2002; Granelli-
Piperno et al., 2005). Therefore, it can be hypothesized thatHHV-8
infects the mucosal epithelium and uses proximal DC, and pos-
sibly monocytes and macrophages, to penetrate the lymphatic
system.
INTERACTION WITH B CELLS
Immature B cells are abundant in the germinal centers of lymph
nodes where they interact with antigen presenting follicular DC
(fDC) and follicular T helper cells, and mature during somatic
hypermutation and clonal expansion (Beltman et al., 2011). B cells
are known to harbor HHV-8 in individuals with KS, PEL, and
MCD (Ambroziak et al., 1995; Cesarman et al., 1995; Cesarman
and Knowles, 1999). In fact, HHV-8 isolated from PEL-derived
cell lines has been used to infect CD19+ B cells in vitro (Mesri
et al., 1996; Rappocciolo et al., 2008). Extensive evidence indi-
cates that peripheral blood B cells from healthy individuals
support productive lytic HHV-8 infection in vitro when acti-
vated with CD40L and IL-4, whereas tonsillar B cells do so
without requiring ex vivo activation (Rappocciolo et al., 2008).
More recent work in our laboratory shows that HHV-8 targets
a range of naïve B cell, IgM memory B cell, and plasma cell-
like populations both after in vitro infection and circulating in
the blood of HIV-1 infected persons with KS (Knowlton et al.,
2014).
B cells could also serve as a reservoir of latent HHV-8, as it has
been reported that the latency-associated nuclear antigen (LANA-
1) can be detected in IgM+ B cells of tonsil origin (Hassman
et al., 2011). It is unclear whether each of these B cell subsets
is directly infected or derived from infected precursors. Inter-
estingly, CD4+ T cells are suggested to support latent HHV-8
infection in B cells by reducing the viral lytic cycle (Myoung
and Ganem, 2011). Finally, HHV-8 DNA is detectable in B
cells of people with PEL (Cesarman et al., 1995), MCD (Dupin
et al., 1999), and KS (Huang et al., 1997; Knowlton et al., 2014).
Studies are needed to more directly assess the role of HHV-8
infection of B cells in endothelial cell transformation associated
with KS.
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Our most recent data show that HHV-8 infected B cells dis-
play a novel polyfunctional cytokine production proﬁle, with an
abundance of IL-6, tumor necrosis factor α (TNFα), macrophage
inhibitory protein-1α (MIP-1α), macrophage inhibitory protein-
1β (MIP-1b) and IL-8 after in vitro infection and in the blood
of HHV-8/HIV-1 co-infected subjects with KS (Knowlton et al.,
2014). This systemic, B cell cytokine and chemokine milieu could
be important in driving endothelial cell outgrowth in KS, and
contribute to the development of HHV-8 associated malignancies.
However, it is still unclear whether various B cell lineage subsets
are equally susceptible to HHV-8 lytic and latent infection, or if
B cell subset precursors are infected and as a result driven into
differentiation. Investigation of the natural progression of HHV-8
infection in B cells, as well as DC and monocytes/macrophages,
is required to bridge the gap in our knowledge between the APC
viral reservoir and transformation of endothelial cells in KS.
INTERACTION WITH T CELLS
Naïve T cells enter lymph nodes through HEVs where they interact
with incoming APC, with both cell types concentrating in para-
cortical zones where T cell activation occurs (Liao and Padera,
2013). The killing function of cytotoxic CD8+ T lymphocytes
(CTLs) in response to intracellular viral antigen presentation is
paramount to clearing the body of infected cells. MHC class
I restricted (CD8+) responses to HHV-8 protein speciﬁc epi-
topes have been detected (Osman et al., 1999; Wang et al., 2002;
Wilkinson et al., 2002). HHV-8 speciﬁc T cell responses in indi-
viduals are not as pronounced as, for example, EBV (Hislop et al.,
2007; Robey et al., 2010), but are nonetheless sufﬁcient to control
primary HHV-8 infection and provide life-long protection from
HHV-8 cancers in immunocompetent individuals (Wang et al.,
2001b).
Follicular DC make up a subset of DC with ontogeny distinct
from mDC and pDC that reside in secondary lymphoid organs
and specialize in antigen presentation (King and Katz, 1990) as
well as provide anti-apoptotic stimuli during activation of B cells
(Park and Choi, 2005). HHV-8 is not detectable, based on mon-
oclonal antibody staining for ORF73 (LANA-1), in fDC within
lymph nodes isolated from KS, PEL, and MCD patients (Dupin
et al., 1999). However, a more comprehensive and sensitive anal-
ysis of lytic and latent gene expression using an established DNA
array of every HHV-8 ORF (Jenner et al., 2001) may be more
insightful for detecting HHV-8 infection of not only fDC but
other target cells. It is important to further investigate if fDC
interactions with T and B cells inﬂuence HHV-8 infection and
pathogenesis.
Previous studies by our group demonstrate that HHV-8 infec-
tion of MDDC in vitro reduces their level of endocytosis as well
as inhibits their ability to activate virus-speciﬁc CD8+ T cells
(Rappocciolo et al., 2006a). In addition, Gregory et al. (2012)
established latent HHV-8 infection of a monocyte cell line in
vitro as a model to study the impact of HHV-8 on monocyte
function. Latent viral infection of the monocyte cell line was
associated with a dampened inﬂammatory and adaptive immune
response, indicated by a decrease in proinﬂammatory cytokine
production and monocyte co-stimulatory molecule expression
associated with T cell activation. It has also been reported
that HHV-8 can enter T lymphocytes from tonsils and result
in an abortive infection (Myoung and Ganem, 2011). Finally,
LC are known to strongly induce activation of CD4+ (Furio
et al., 2010) and CD8+ T cells (Klechevsky et al., 2008), open-
ing the possibility that HHV-8 directly affects this ability of LC
to activate T cells. In sum, whether virus is interacting with
MDDC and monocytes in circulation or tissue, or with LC and
SMDC in the mucosa, T cell responses are likely altered. This
must be viewed however, with the fact that HHV-8 infection
does not result in high-risk for disease in immunocompetent
people.
DC IN HHV-8-ASSOCIATED DISEASE
Despite the wide range of permissive and potentially suscep-
tible host cells and substantial immune modulation associated
with infection, most HHV-8-associated pathologies only occur
when the immune response is compromised by HIV-1 co-
infection or another secondary mechanism such as immuno-
suppression caused by anti-rejection drugs during organ trans-
plantation and by older age. AIDS-associated cancers, including
KS and non-Hodgkin’s lymphomas such as PEL are strongly
inﬂuenced by T cell immunosuppression (Frisch et al., 2001).
In addition, KS has been shown to develop more quickly if
primary HHV-8 infection occurs after HIV-1 infection (Jacob-
son et al., 2000). Based on such epidemiological data, sub-
standard T cell function and consequent ineffective control
of virus lytic reactivation are a major basis for susceptibil-
ity to HHV-8 disease. This potentially implicates abnormalities
in DC as a basis for such T cell dysfunction during HHV-8
infection.
KAPOSI’S SARCOMA
Human herpesvirus 8 was initially isolated from tissue samples of
AIDS-associated KS patients and identiﬁed as a unique gamma-
herpesvirus similar to but distinct from EBV (Chang et al., 1994).
Today, HHV-8 is associated with all forms of KS irrespective of
immunocompromised status. Perhaps what is most puzzling is
that the extensive array of lytic and latent gene products encoded
by HHV-8 that mimic host immunoregulatory proteins as well as
growth factors are insufﬁcient to cause KS (Mesri et al., 2010). We
(Knowlton et al., 2012) and others (Rezaee et al., 2006) hypothe-
size that a speciﬁc cytokine and chemokine environment enhances
outgrowth of HHV-8 infected, vascular endothelial cells. It is
therefore likely that the impact of HHV-8 infection of DC on
T and B cell cytokine and chemokine production is important in
this pathogenic process.
From a historical perspective, DDC were associated with both
AIDS-associated and non-AIDS-associated KS lesions prior to the
identiﬁcation of HHV-8 as the etiological agent of KS (Nickoloff
and Grifﬁths, 1989), yet data concerning DDC in AIDS-associated
KS are limited and need to be expanded. In addition, multiple
cell types associated with the dermal and epidermal layers in KS
lesions support their role in productive HHV-8 infection. Thus,
HHV-8 DNA has been detected in spindle cells and endothelial
cells within and overlaying KS lesions (Nickoloff and Grifﬁths,
1989; Boshoff et al., 1995; Reed et al., 1998). DC quantity and
functional quality are lowered or skewed in classic KS patients.
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These patients present with a lower frequency of MDDC and
pDC, as well as an up-regulation of the endocytic receptor CD91
and decrease in expression of the T cell maturation factor IL-
12 compared to HHV-8 positive individuals without KS (Della
Bella et al., 2006). The likelihood of KS development and time
to progression after HHV-8 seroconversion varies based on his-
tory of previous infections, HIV-1 co-infection, and behavioral
characteristics (Armenian et al., 1993). In addition, highly active
antiretroviral therapy (HAART) greatly extends the time to pro-
gression to AIDS (Hogg et al., 1999), and is associated with a
decrease inHHV-8 replication andKS regression (Gill et al., 2002).
Therefore, there may be events interfering with the anti-HHV-8
T cell response that begin years prior to disease. T cell responses
to HHV-8 antigens and the role of DC in these have yet to be
compared longitudinally from infection to KS development, and
may reveal important implications of immune suppression and
KS. There is a similar limited amount of in vivo data assessing T
cells and DC in PEL and MCD.
PRIMARY EFFUSION LYMPHOMA
Primary effusion lymphoma is an uncommon B cell lymphoma
and comprises 4% of all HIV-1-related non-Hodgkin’s lymphoma
cases (Simonelli et al., 2003). The presence of HHV-8 infection of
oncogenic cells in HIV-1-related (Cesarman et al., 1995; Carbone
et al., 1996b; Otsuki et al., 1996; Gessain et al., 1997) and non-
HIV-1-related PEL (Nador et al., 1995; Carbone et al., 1996a; Said
et al., 1996) is well established, however, the impact of infection
on disease development remains unclear. Genome wide analysis
of HHV-8 gene expression in latently infected PEL cell lines has
demonstrated that multiple virally encoded products, including
ORF71 and 72, v-FLIP, and v-cyclin, are expressed (Jenner et al.,
2001), which could inﬂuence growth characteristics of the infected
and uninfected cells.
As seen in KS, there is evidence that the functional quality
and phenotype of DC are irregular in patients that present with
PEL. Similarly, DC functional abnormalities have been associated
with several cancers includingmelanomaand chronic lymphocytic
leukemia (Enk et al., 1997; Orsini et al., 2003). Cirone et al. (2008)
demonstrated a reduction in immature DC (iDC) differentiation
from CD14+ monocytes, as well as phenotypic differences, in the
presence of multiple individual PEL cell lines when co-cultured in
vitro, compared to iDC derived in the absence of PEL cell lines.
This suggests that in addition to reducing the function of DC,
HHV-8 can inhibit the activation and differentiation of monocytes
into DCs.
MULTICENTRIC CASTLEMAN’S DISEASE
Multicentric Castleman’s disease is another rare lymphoprolifera-
tive disease highly correlated with HIV-1 infection (Oksenhendler
et al., 1996) that occurs less commonly in HIV-1 seronegative indi-
viduals, the type of cases within which it was initially described
(Castleman et al., 1956). Frequent co-presentation of MCD and
KS raised questions regarding the relationship between MCD and
HHV-8. During the same year HHV-8 was isolated from PEL
cases, Soulier et al. (1995) detected HHV-8 in 100% of HIV-1-
associated MCD cases and 41% of HIV-1 negative MCD cases.
Interestingly, fDC sarcoma is a rare malignant neoplasm that has
been associated with Castleman’s disease (Chan et al., 2001; Farah
et al., 2005), but not yet MCD speciﬁcally. Small percentages of
fDC from lymph node and spleen samples of MCD cases have
been found to express HHV-8 LANA-1. Interestingly, these same
fDC are thought to facilitate the increase of T cell inﬁltration
into these secondary lymphoid organs (El-Daly et al., 2010). This
suggests that fDC serve as functional soldiers in the DC arm of
defense.
MULTIPLE MYELOMA
Brieﬂy, the design anduse of DC-based treatment and vaccines tar-
getingmultiplemyelomawas heavily considered and thought to be
promising in the late 1990s. HHV-8 infectionwas initially found in
bone marrow DC of patients with multiple myeloma (Rettig et al.,
1997). However, evidence since has concluded that bone marrow-
derived (Mitterer et al., 1998), peripheral blood mononuclear cell
(PBMC)-derived (Cull et al., 1998; Yi et al., 1998), and CD34 posi-
tive cell-derived (Mitterer et al., 1998) DC from myeloma patients
do not contain HHV-8 sequences. In fact, the absence of HHV-8
in DC of these patients increases the feasibility of an autologous,
DC-based immunomodulatory therapy for multiple myeloma.
However, such treatments have rarely been successful in clinical
trials.
EFFECT OF HHV-8 INFECTION ON DC
Human herpesvirus 8 encodes many cellular protein homologs,
such as vIL-6 (Neipel et al., 1997), vMIP-I and -II (Moore et al.,
1996), vIRF-1 (Lin et al., 2001), and vGPCR (Cesarman et al.,
1996), that could dysregulate the host immune response and
increase survival of latently infected cells (Jenner et al., 2001),
thus playing a major role in HHV-8 pathogenesis. DC function is
notably altered in KS, PEL, and MCD cases as previously described
in this review, and the impact of direct HHV-8 infection of DC
(Chan et al., 2001; Della Bella et al., 2006; Cirone et al., 2008) cor-
relates with a dampening of DC functionality. A recent report
suggests that one manner by which HHV-8 alters DC function
is by blocking autophagy, a type of non-apoptotic programmed
cell death, through STAT3 activation and the production of IL-6,
IL-10, and IL-23 in MDDC in vitro (Santarelli et al., 2014). In
addition, HHV-8 infection of DC precursor monocytes has been
directly correlated with an inhibition of maturation into iDC and
a decrease in functional stimulation of lymphocytes (Cirone et al.,
2007).
A dysfunction in immune stimulation of infected DC is sup-
ported by earlier studies revealing two HHV-8 encoded proteins,
K3 and K5, with essential roles in down-regulating MHC class
I molecules via endocytosis from the surface of infected cells
(Coscoy and Ganem, 2000; Ishido et al., 2000). Furthermore,
despite sharing a 40% amino acid homology, structural differ-
ences between K3 and K5 are responsible for the speciﬁcity of
the class I subtype targeted by each (Ishido et al., 2000). While
K3 strongly down-regulates all four MHC class I types, K5 only
targets HLA-A, B, and C, the latter of which is only weakly down-
regulated (Ishido et al., 2000). Interestingly, it has been suggested
that K3 and K5 have the ability to decrease levels of DC-SIGN and
DC-SIGNR on the surface of virus-infected HEK293 kidney cells
(Lang et al., 2013). HHV-8 encoded LANA1 inhibits MHC class I
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presentation on the surface of HEK293 (Kwun et al., 2011). How-
ever, it has yet to be revealed if LANA1 functions in this manner in
DC. HHV-8 also produces multiple microRNAs, all of which are
encoded within latency-associated genes (Samols et al., 2005), and
are detectable in latently infected B cell lines suggesting that they
play a role in inducing and/or maintenance of HHV-8 latency (Cai
et al., 2005). However, their impact onDC function is not clear and
could be studied with RNA silencing technology.
Despite an increased progression to disease following immune
suppression, it is puzzling how otherwise healthy individuals
remain capable of minimizing HHV-8 pathogenesis even with
viral factors directly attempting to inhibit the function of DC
and other immune cells. Addressing this enigma requires in
depth studies of HHV-8 infection of naturally targeted cells
including DC.
FUNCTIONAL DC RESPONSES TO HHV-8 INFECTION
Despite seemingly extensive attempts by the virus to inhibit
DC function and evade the host immune response, reports
support that DC can contribute positively to the host’s bat-
tle against HHV-8 infection, as also described in innate and
adaptive responses against EBV (Munz, 2014). Up-regulation of
DC-SIGN expression on MDDC and B cells during maturation
can be induced by IL-4 and CD40L (Relloso et al., 2002; Rap-
pocciolo et al., 2006b). In contrast, type 1 anti-inﬂammatory
cytokines such as interferon (IFN) and TGF-β trigger down reg-
ulation of DC-SIGN expression of MDDC (Relloso et al., 2002).
Together these data suggest that DC-SIGN is positively regulated
in response to extracellular pathogen-based immune responses
and negatively regulated in response to intracellular pathogen-
based responses such as viral infections. This theoretically should
help decrease the number of HHV-8 susceptible cells in the host.
We have shown that HHV-8 infected MDDC in vitro display
a Th2-skewed cytokine response characterized by a signiﬁcant
increase in IL-6, MIP1α, and MIP1β expression within 72 h post-
infection. Furthermore, while IL-12p40 increases, production of
IL-12 p70 is signiﬁcantly lower in infected MDDC compared
to controls (Hensler et al., 2009). IL12 p70 production is neces-
sary for the induction of an effective CTL response (Wang et al.,
2001b). However, there is also evidence that DC derived from
HIV-1 infected patients with KS retain the ability to prime CD8+
T cells against HHV-8 speciﬁc antigens (Stebbing et al., 2003),
even though they may lack other functional abilities previously
discussed.
Plasmacytoid dendritic cells are a subset of DC comprising
less than 1% of PBMC that focus on recognizing and respond-
ing to viral infections via TLR signaling (West et al., 2011) and
type 1 IFN production (Liu, 2005). HHV-8 can infect pDC result-
ing in cell activation and IFNα production as a result of TLR9
induced signaling prior to the production of a viral factor that
reduces TLR9 signaling and subsequent IFNα production (West
et al., 2011). The receptor by which HHV-8 infects pDC has not
been identiﬁed. However, pDCprecursors expressDC-SIGN, indi-
cating they could be susceptible to HHV-8 infection (Soilleux
et al., 2002). Alternatively, uninfected DC at sites of infection
could recognize and engulf distressed, lytically infected cells, such
as apoptotic B cells, macrophages, and endothelial cells (Ueno
et al., 2007). All together these sustained DC functions should
contribute to minimizing HHV-8 pathogenesis and allowing oth-
erwise healthy individuals to handle this chronic infection over a
lifetime.
CONCLUSION
The natural progression of HHV-8 infection of humans is not
fully understood. However, it most commonly begins with entry
though a mucosal surface, and likely spreads through the lym-
phatic system through which it accesses immune cells in mucosal
associated lymphoid tissue and the circulatory system. The expres-
sion of viral cytokines, vGPCR, and microRNA homologs suggests
that this virus goes to a great extent to alter host cellular activities
in favor of viral replication, disease, and survival. It is, therefore, an
enigma how humans deal with chronic life-long HHV-8 infections
with minimal morbidity unless otherwise immunocompromised.
It is likely that, as with most chronic viral infections, severe disease
is not an endpoint goal of HHV-8 in healthy individuals. The virus
likely hinders the pathogen detection and surveillance arm of the
immune system sufﬁciently to remain hidden, possibly within B
cells.
Despite a non-robust lytic replication cycle in DC, abortive
HHV-8 infection is associated with dysfunctional maturation and
a dampened T helper-1 response and up-regulation of T helper-
2 cytokine production, yet such responses are sufﬁcient to limit
pathogenesis. Intracellular signaling through virus attachment
alone may be enough to induce these effects and eliminate the
pressure on the virus to establish lytic replication within DC,
particularly if it can reproduce using other cells, such as B cells,
macrophages, and endothelial cells without traumatic pathogene-
sis. This suggests HHV-8 intricately alters the immune response to
prolong survival while conserving its surrounding environment,
the host.
Human herpesvirus 8 infection of an immunocompromised
host increases the likelihood of HHV-8 associated disease develop-
ment, such as KS. In addition, immune suppression after HHV-8
infection due to, for example, secondary HIV-1 infection or organ
transplantation, is also associated with disease development. We
theorize, as others have in the past (Osman et al., 1999), that
the dampened immune activation and speciﬁc HHV-8 responses
controlling chronic HHV-8 infection in healthy persons are not
sufﬁcient in a signiﬁcantly immune compromised environment.
The tug-of-war between this virus and the human host appears
sophisticated. However, the process has not been fully elucidated,
and uncovering the components involved should continue to be of
great interest to the ﬁelds of cancer biology, virology, immunology,
and cell biology.
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